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Abstract 
Background: Human immunodeficiency virus type 2 (HIV-2) is often distinguished clinically by lower viral loads, 
reduced transmissibility, and longer asymptomatic periods than for human immunodeficiency virus type 1 (HIV-1). 
Differences in the mutation frequencies of HIV-1 and HIV-2 have been hypothesized to contribute to the attenuated 
progression of HIV-2 observed clinically.
Results: To address this hypothesis, we performed Illumina sequencing of multiple amplicons prepared from cells 
infected with HIV-1 or HIV-2, resulting in ~4.7 million read pairs and the identification of ~200,000 mutations after data 
processing. We observed that: (1) HIV-2 displayed significantly lower total mutation, substitution, and transition muta-
tion frequencies than that of HIV-1, along with a mutation spectrum markedly less biased toward G-to-A transitions, 
(2) G-to-A hypermutation consistent with the activity of APOBEC3 proteins was observed for both HIV-1 and HIV-2 
despite the presence of Vif, (3) G-to-A hypermutation was significantly higher for HIV-1 than for HIV-2, and (4) HIV-1 
and HIV-2 total mutation frequencies were not significantly different in the absence of G-to-A hypermutants.
Conclusions: Taken together, these data demonstrate that HIV-2 exhibits a distinct mutational spectrum and a lower 
mutation frequency relative to HIV-1. However, the observed differences were primarily due to reduced levels of 
G-to-A hypermutation for HIV-2. These findings suggest that HIV-2 may be less susceptible than HIV-1 to APOBEC3-
mediated hypermutation, but that the fidelities of other mutational sources (such as reverse transcriptase) are rela-
tively similar for HIV-1 and HIV-2. Overall, these data imply that differences in replication fidelity are likely not a major 
contributing factor to the unique clinical features of HIV-2 infection.
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Background
Human immunodeficiency virus type  1 (HIV-1) infects 
approximately 35 million individuals worldwide and 
has resulted in about 39 million deaths since the onset 
of the AIDS pandemic (http://www.unaids.org). Within 
infected individuals, HIV-1 undergoes rapid genetic 
diversification, promoting the acquisition of drug resist-
ance, evasion of the host immune response, and altera-
tions in cell tropism. Genetic diversification is, in turn, 
driven by large population sizes and high rates of repli-
cation, recombination, and mutation. HIV-1 has been 
found to mutate on the order of 10−4 to 10−5 muta-
tions/base pair/cycle (m/bp/c), corresponding to ~0.1–1 
mutations per genome synthesized [1–5]. HIV-1 thus 
mutates about 10,000–100,000 times faster than eukary-
otic genomic DNA [6]. Multiple viral and cellular factors 
influence both the rates and types of mutations produced 
during viral replication. Reverse transcriptase (RT) is 
likely a major generator of mutations in vivo, as it is tre-
mendously error-prone in  vitro (mutation rates >10−4 
m/bp/c), primarily due to a lack of proofreading activity 
[7, 8]. RNA polymerase II can also introduce mutations 
when transcribing the viral RNA genome, but less than 
that of RT [3]. Cellular DNA polymerases can introduce 
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mutations when replicating the proviral DNA integrated 
into the cellular genome; however, these enzymes have 
been assumed to minimally contribute to HIV-1 variation 
due to the high fidelity of genomic DNA replication [6]. 
In addition, apolipoprotein B mRNA-editing enzyme cat-
alytic polypeptide-like 3 (APOBEC3) proteins can induce 
G-to-A hypermutation, particularly in the absence of 
Vif [9, 10]. APOBEC3-mediated hypermutation is often 
lethal to virus replication, but accumulating evidence 
suggests that APOBEC3 proteins can in some cases pro-
mote genetic diversification and the evolution of new 
variants conferring drug resistance or altered cell tropism 
[11–15]. Other factors, such as dNTP pool levels [16], 
other viral proteins (Vpr) [17, 18], and cell type [19] have 
been shown to influence HIV-1 mutagenesis as well.
Relative to HIV-1, human immunodeficiency virus type 
2 (HIV-2) infection is often marked clinically by lower 
viral loads, reduced transmissibility, and longer asymp-
tomatic periods in infected individuals [20, 21]. Differ-
ences in the mutation frequencies of HIV-1 and HIV-2 
have been hypothesized to contribute to the attenuated 
progression of HIV-2 observed clinically. Specifically, a 
lower mutation rate for HIV-2 would be expected to limit 
genetic diversification, which could in turn reduce viral 
fitness and/or attenuate viral pathogenicity. Consistent 
with this hypothesis, viral variants with increased rep-
lication fidelity have been shown to result in impaired 
viral fitness and virulence in many other RNA viruses 
[22–26]. In further support of this hypothesis, HIV-2 has 
been found to evolve less quickly than HIV-1 [27, 28], 
though one report has found the opposite [29]. However, 
it should be noted that evolutionary rates depend on a 
wide variety of factors besides the mutation rate, such as 
replication rate, population size, and selective pressures. 
In addition, the HIV-2 RT contains a highly conserved 
V75I polymorphism, a drug resistance-associated muta-
tion in HIV-1 that improves RT fidelity [30, 31]. Lastly, 
HIV-2 has been shown to be less sensitive than HIV-1 to 
APOBEC3G activity, potentially diminishing the contri-
bution of APOBEC3G to viral mutagenesis [32].
In order to compare mutation frequencies and spec-
tra between HIV-1 and 2, we performed Illumina high-
throughput sequencing of proviral DNA from cells 
infected with HIV-1 or 2. We found that HIV-2 displayed 
lower total, substitution, and transition mutation fre-
quencies than HIV-1, particularly due to reduced levels 
of G-to-A transition mutations. We also observed low-
level G-to-A hypermutation in both HIV-1 and HIV-2 
that was consistent with the activity of APOBEC3 pro-
teins. Intriguingly, HIV-2 demonstrated significantly 
lower levels of G-to-A hypermutation than HIV-1. After 
exclusion of G-to-A hypermutants, total mutation fre-
quencies were not significantly different between HIV-1 
and HIV-2. Together, these data support the conclusion 
that differences in general replication fidelity are likely 
not a primary driver of the unique clinical features of 
HIV-2 infection.
Results
Characterization of background errors induced by PCR 
and Illumina sequencing
In order to compare mutation frequencies and spectra 
between HIV-1 and HIV-2, single cycle infections with 
HIV-1 or HIV-2 were performed at a high MOI (1 million 
U373-MAGI-X4 cells per replicate infected at an MOI of 
1.0, see “Methods”; Figure 1). In this assay, producer cells 
cannot be re-infected due to a lack of the appropriate 
receptor and co-receptor, and target cells likewise can-
not be re-infected due to disruption of the env genes in 
the HIV-1 and HIV-2 vectors. Genomic DNA was puri-
fied from infected cells and first subjected to quantitative 
PCR (qPCR) in order to determine the level of plasmid 
carryover from transfections. Plasmid carryover was 
quantified either by: (1) determining the plasmid back-
bone copy number (by measuring the ampicillin resist-
ance gene) and dividing by the proviral copy number, 
or (2) determining the proviral copy number from heat-
inactivated viral infections and dividing by the proviral 
copy number from un-treated infections (see “Methods”). 
We found that the level of plasmid carryover for HIV-1 
was 0.2% when measured by either method, while the 
level of carryover was 2.8 or 1.4% for HIV-2, depending 
on the approach used (Additional file  1: Table S1). The 
significantly higher level of plasmid carryover for HIV-2 
likely reflects the reduced infectivity of HIV-2 viral 
stocks, which resulted in larger volumes of viral stocks 
being used during infection. These results are compa-
rable to those obtained in another study [5] and are too 
low to significantly impact measured mutation frequen-
cies. Next, amplicons were prepared from proviral DNA 
for Illumina sequencing. In total, 12 samples were ana-
lyzed—three experimental replicates each of HIV-1, 
HIV-2, and HIV-1 and HIV-2 plasmid amplifications as 
controls to determine levels of background errors. Fur-
ther, for each sample, five amplicons were prepared (Gag, 
Vif, HSA, EGFP-1, and EGFP-2), representing a mixture 
of viral (Gag, Vif ) and marker (HSA, EGFP-1, EGFP-2) 
gene targets. Libraries were prepared individually from 
samples in order to prevent inter-sample recombination 
during library construction. Following this, all librar-
ies were pooled and subjected to 2  ×  150 paired-end 
sequencing on the Illumina MiSeq, resulting in ~4.7 mil-
lion total read pairs after processing, or an average of 
~79,000 read pairs/amplicon/sample (Additional file  2: 
Table S2). After stringent filtering of Illumina data, the 
mutation frequencies (expressed as mutations per base 
Page 3 of 17Rawson et al. Retrovirology  (2015) 12:60 
pair, or m/bp) were determined for all samples, both in 
terms of total mutations and every possible subdivision 
(i.e. substitutions, transitions, transversions, etc.). Muta-
tion counts, frequencies, and relative percentages are 
listed in Additional file  3: Dataset S1, both combined 
across all five amplicons and separated by amplicon.
After sequencing, the first objective was to utilize the 
plasmid controls to characterize the frequencies and 
spectra of background errors (i.e. errors from PCR or 
sequencing) in order to determine the extent to which 
biological mutations could be detected above the level of 
the background. The average mutation frequencies of the 
plasmid controls were 2.8 (HIV-1) and 2.6 (HIV-2) ×10−4 
m/bp (Figure 2a; Additional file 3: Dataset S1), consistent 
with a recent investigation into background error during 
amplicon sequencing on the Illumina MiSeq [33]. Most 
of the background errors observed were substitutions, 
with insertions and deletions comprising only 4.3–4.9% 
of total mutations. Of the substitutions, transversions 
and transitions were observed at similar frequencies: 
1.2–1.4 × 10−4 m/bp for transversions and ~1.2 × 10−4 
m/bp for transitions, such that each category composed 
~half of all mutations (Figure 2c). However, as described 
in “Methods”, plasmid error hotspots (i.e. positions highly 
prone to background error) were masked prior to this 
analysis, and in the absence of such masking transver-
sions occurred ~2.5-fold more often than transitions. 
Thus, our findings are consistent with previous reports 
that have observed a bias of Illumina sequencing (using 
a variety of different platforms and library preparation 
methods) toward transversion types [33–36]. Inter-
estingly, among the eight possible transversion types, 
background transversion errors were non-randomly 
distributed (Additional file  4: Figure S1). Specifically, 
background transversions were strongly biased toward 
C-to-A and G-to-T transversions, which composed 74% 
(HIV-1) or 73% (HIV-2) of all transversions. C-to-A and 
G-to-T are reciprocal mutational types, and these muta-
tions may be due to oxidative conversion of guanine to 
8-oxoguanine or due to Illumina imaging artifacts (see 
“Discussion”). Background errors were distributed quite 
evenly across the five amplicons (Figure 2b), demonstrat-
ing that no individual amplicon was particularly prone to 
background errors.
In addition to analyzing background error frequencies 
and spectra, the frequency of intra-sample recombina-
tion due to PCR was also examined. While PCR-medi-
ated recombination is not known to be mutagenic, 
recombination could affect associations between muta-
tions. We attempted to minimize recombination from 
PCR by stopping reactions after 30 cycles of amplifica-
tion, corresponding to the ~end of the log-linear phase 
of amplification, after which recombination occurs at a 
much higher rate due to saturation of dNTPs and primers 
[37–39]. Intra-sample recombination frequencies were 
determined using genetic markers that were incorpo-
rated into the plasmid control amplifications (see “Meth-
ods”). Under these amplification conditions, intra-sample 
Figure 1 Experimental strategy for investigating HIV-1 and HIV-2 mutagenesis by Illumina DNA sequencing. Vector virus stocks were produced by 
co-transfecting 293T cells with HIV-1 or HIV-2 Env-deficient vectors and HIV-1 or HIV-2 CXCR4-tropic Env expression constructs. Virus stocks were 
concentrated, DNase I-treated to reduce plasmid carryover, and titered in U373-MAGI cells. To prepare samples for Illumina sequencing, 1 × 106 
U373-MAGI cells were infected at an MOI of 1.0, generating approximately 1 × 106 proviruses per experimental replicate. This assay represents a 
single round of viral replication, as producer cells and target cells cannot be re-infected, due to a lack of receptor or Env expression, respectively. 
Polymerase chain reaction (PCR) of five amplicons (Gag, Vif, HSA, EGFP-1, and EGFP-2) was performed from the proviral DNA. Amplicons from 
the HIV-1 and HIV-2 proviral DNAs were either identical (HSA, EGFP-1 and 2) or homologous (Gag and Vif ) in sequence. The EGFP-1 and EGFP-2 
amplicons represent non-overlapping segments of the egfp gene. Sequencing libraries were prepared from the amplicons, pooled in an equimolar 
fashion to normalize coverage, and subjected to 2 ×150 bp sequencing on the Illumina MiSeq, generating approximately 4.7 million read pairs after 
data processing.
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recombination was observed at frequencies of ~2–3% 
of the maximum observable in the assay, demonstrating 
that recombination from PCR was relatively rare (Addi-
tional file 5: Table S3).
We next compared the mutation frequencies and spec-
tra of the HIV-1 and 2 biological samples to that of the 
plasmid controls in order to determine which types of 
mutations could be detected above background levels. 
HIV-1 and HIV-2 exhibited average mutation frequen-
cies of 6.9 (HIV-1) and 3.1 (HIV-2)  ×  10−4 m/bp (Fig-
ure 2a; Additional file 3: Dataset S1). The total mutation 
frequency of HIV-1 was significantly higher than the 
corresponding plasmid control (p  <  0.001). In contrast, 
the HIV-2 total mutation frequency was not signifi-
cantly higher than the plasmid control (p = 0.40). Upon 
separating out the major classes of mutations, we found 
that this was primarily due to high levels of transver-
sions in the plasmid controls. Transversions occurred 
at frequencies of 1.4 (HIV-1) or 1.2 (HIV-2) ×  10−4 m/
bp in the plasmid controls (Figure  2a), values that were 
not significantly different from that of the biological 
samples. Similar to transversions, insertion frequen-
cies did not significantly vary between biological sam-
ples and plasmid controls, and deletion frequencies 
were only significantly higher than plasmid for HIV-2 
(p = 0.02, Additional file 3: Dataset S1). However, inser-
tions and deletions had little impact on overall muta-
tion frequencies because they were much less frequent 
(3–6% of total mutations) than substitutions (Figure 2c). 
Notably, although the HIV-2 total mutation frequency 
was not significantly higher than its corresponding plas-
mid control, transition frequencies [5.8 (HIV-1) and 2.0 
(HIV-2) × 10−4 m/bp] were significantly higher than the 
plasmid controls for both viruses (HIV-1: p < 0.001; HIV-
2: p = 0.038). These differences were also reflected in the 
mutation spectra, as transitions comprised 84% (HIV-1) 
Figure 2 HIV-2 has a lower mutation frequency and distinct mutation spectrum relative to HIV-1. a Mutation frequency analysis. Mutation frequen-
cies were calculated by dividing the number of mutations by the number of reference bases (mutations + wild-type bases) and are expressed as 
mutations/bp, or m/bp. Mutation frequencies were determined for HIV-1 and HIV-2, as well as for plasmid controls to assess background error levels. 
b Transition frequency analysis. Transition frequencies were compared across the five different amplicons subjected to Illumina DNA sequencing. c 
Mutation spectra analysis. Mutation spectra were determined by dividing the frequency of each type of mutation by the total mutation frequency, 
with the results expressed as a percentage of total mutations. Data in all panels represent the mean of three experimental replicates, with error bars 
indicating the standard deviation. Asterisks denote statistically significant differences between HIV-1 and 2 (*p < 0.05, ***p < 0.001, N.S. not signifi-
cant). The actual numbers of read pairs, mutations, and reference bases are listed in Additional file 3: Dataset S1.
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or 66% (HIV-2) of total mutations in the biological sam-
ples but only 44% (HIV-1) or 48% (HIV-2) in the plasmid 
controls (Figure 2c). Importantly, many previous reports 
have demonstrated that transitions predominate during 
the replication of HIV-1, generally comprising 70–90% of 
all substitutions [1–4, 17, 19, 40]. Thus, considering that 
transitions are more relevant to HIV-1 replication and 
that they were detected at levels significantly higher than 
the background, most downstream analyses focused on 
transition mutational types.
HIV‑2 exhibits a lower mutation frequency and an altered 
mutation spectrum relative to that of HIV‑1
We next compared HIV-1 and HIV-2 mutation frequen-
cies in order to test our initial hypothesis that HIV-2 
would display a lower mutation frequency than HIV-
1. We found that HIV-1 had a significantly higher total 
mutation frequency, as well as higher frequencies of 
substitutions and transitions, than HIV-2 (relative dif-
ferences of 2.3, 2.3, and 2.9-fold, respectively; all p values 
<0.001) (Additional file 3: Dataset S1; Figure 2a). In con-
trast, the levels of transversion mutations were not sig-
nificantly different between HIV-1 and HIV-2 (p = 0.32). 
The observed differences in transition frequencies were 
primarily due to an approximately 6.9-fold higher fre-
quency (p  <  0.001) of G-to-A transition mutations with 
HIV-1 than with HIV-2 (Additional file  3: Dataset S1). 
Less striking, but statistically significant, differences were 
observed for several other types of transitions as well. 
HIV-1 displayed a 1.1-fold higher frequency of A-to-
G transitions (p =  0.049) than HIV-2, while HIV-2 dis-
played a 1.5-fold higher frequency of C-to-T transitions 
than HIV-1 (p = 0.0019). The frequency of T-to-C transi-
tions was not significantly different between HIV-1 and 
HIV-2. Consistent with these results, the mutation spec-
trum of HIV-1 was much more heavily biased toward 
G-to-A transition mutations than for HIV-2 (66 vs. 22% 
of total mutations, Figure 2c). Overall, these data demon-
strate that the HIV-1 mutation frequency is significantly 
higher than that of HIV-2, predominantly due to substan-
tially higher levels of G-to-A transition mutations.
Mutation frequencies vary across amplicons for HIV‑1 
and HIV‑2
We hypothesized that specific amplicons might be more 
or less error-prone than others due to features of the pri-
mary sequence (such as homopolymeric runs), second-
ary structures, or the relative positioning of the amplicon 
within the viral genome. To address this, transition 
frequencies were compared across the five amplicons 
analyzed in this study. As previously indicated, transi-
tions in the plasmid controls were distributed relatively 
evenly across the five amplicons, demonstrating that 
no individual amplicon was particularly prone to back-
ground transition mutations (Figure 2b). In contrast, for 
HIV-1, it was found that most transitions were concen-
trated in the EGFP-1 amplicon and, to a lesser extent, the 
Vif amplicon (Figure 2b). The EGFP-1 and Vif amplicons 
together accounted for about 74% of all transitions in 
HIV-1. The relative order of transition frequencies among 
the amplicons was found to be EGFP-1  >  Vif  >  EGFP-2 
≈  HSA  ≈  Gag, with all indicated differences between 
amplicon pairs being statistically significant (p  <  0.001). 
Since G-to-A transitions predominated for HIV-1, the 
observed differences could potentially be explained by 
varying nucleoside content between amplicons. However, 
the amplicons contained relatively similar frequencies of 
deoxyguanosine, ranging from 19.6 to 31.2%. Further, the 
Vif amplicon actually contained the lowest deoxyguano-
sine content of the five amplicons, despite having the sec-
ond highest transition frequency. For HIV-2, transition 
frequencies were much more evenly distributed between 
amplicons than for HIV-1, with a maximal difference 
of ~1.3-fold (between Gag and EGFP-2). We also com-
pared transition frequencies between HIV-1 and HIV-2 
at the level of individual amplicons. HIV-1 was found to 
have a higher frequency of transitions than HIV-2 in all 
amplicons except Gag (p = 0.12 for Gag; p < 0.001 for all 
other amplicons); however, the greatest differences were 
observed in the EGFP-1 and Vif amplicons (7.2 and 2.9-
fold differences, respectively).
Detection of G‑to‑A hypermutation in HIV‑1 and HIV‑2
Considering the high levels of G-to-A transition 
mutations (particularly for HIV-1) that we observed 
 (Figure  2c), we next investigated whether HIV-1 or 2 
displayed evidence of G-to-A hypermutation. G-to-A 
hypermutation could potentially arise from the activity 
of APOBEC3 proteins, though relatively little APOBEC3 
activity was expected in this particular experimental sys-
tem (see “Discussion”). In these analyses, hypermutants 
were defined as read pairs (~120 bp in length) that con-
tained two or more mutations of the same type within 
the read pair. In addition to analyzing G-to-A hypermu-
tants, we determined frequencies of other possible types 
of transition hypermutants (A-to-G, C-to-T, and T-to-C) 
as well, as HIV-1 A-to-G hypermutants have occasionally 
been reported in the literature [4, 41]. All hypermutant 
counts and frequencies (defined as hypermutant read 
pairs/all read pairs) are tabulated in Additional file  6: 
Dataset S2, either combined across all amplicons or sepa-
rated by amplicon.
In HIV-1, the frequency of G-to-A hypermutants was 
approximately 7.9 × 10−3 (or ~1 of 127 read pairs), while 
in HIV-2 the frequency was much lower, approximately 
2.8  ×  10−4 (or 1 of 3,623 read pairs) (Figure  3a). The 
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average G-to-A hypermutation frequencies were about 
1,060-fold higher for HIV-1 or about 17-fold higher for 
HIV-2 as compared to their corresponding plasmid 
controls, respectively. HIV-1 and HIV-2 G-to-A hyper-
mutant frequencies were significantly higher than the 
plasmid controls in all five amplicons examined (p-values 
ranging from <0.001 to 0.01). The G-to-A hypermutation 
frequency was much higher (i.e., about 28-fold) in HIV-1 
than observed in HIV-2 (p < 0.001), demonstrating that 
HIV-2 was less susceptible to G-to-A hypermutation in 
this experimental system. This trend was significant in 
all five amplicons examined (p  <  0.001). Other types of 
transition hypermutants were also observed (Figure 3a), 
but they were far less frequent than G-to-A hypermu-
tants and were not observed at levels significantly higher 
than that of the plasmid controls. In HIV-1, G-to-A 
hypermutants comprised about 98% of all transition 
hypermutants, indicating a clear dominance over other 
possible types of transition hypermutants. When sub-
divided by amplicon, the distribution of HIV-1 G-to-A 
Figure 3 HIV-1 demonstrates higher G-to-A hypermutant frequencies than HIV-2. a The frequencies of each type of transition hypermutant were 
compared between HIV-1, HIV-2, and the plasmid controls. For this analysis, hypermutants were defined as read pairs containing two or more muta-
tions of the indicated type within an individual read pair (approximately 120 bp in length). The frequency of hypermutation was then calculated by 
dividing the number of hypermutant read pairs by all read pairs. b The frequency of G-to-A hypermutation was compared across all five amplicons 
examined by Illumina DNA sequencing. c The degree of G-to-A hypermutation was analyzed by determining the numbers of G-to-A mutations 
within hypermutant read pairs. d The dinucleotide context of G-to-A mutations from G-to-A hypermutants was determined and expressed as a 
percentage of the total. Data in panels a, b, and d represent the mean of three experimental replicates, with error bars representing standard devia-
tion, while data in panel c represent the total (i.e. compiled) data. Asterisks denote statistically significant differences between HIV-1 and 2 (*p < 0.05, 
***p < 0.001, N.S. not significant). The actual numbers of G-to-A hypermutant read pairs and reference read pairs are listed in Additional file 6: 
Dataset S2.
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hypermutation was found to resemble that of all transi-
tions (Figure 2b), with most G-to-A hypermutation con-
centrated in the EGFP-1 and Vif amplicons (Figure  3b). 
In fact, after removal of G-to-A hypermutants, transition 
frequencies were very consistent across all five ampli-
cons, demonstrating that G-to-A hypermutants were 
responsible for the elevated transition frequencies in 
EGFP-1 and Vif (Additional file 7: Figure S2). The overall 
observed trend of G-to-A hypermutation among ampli-
cons in HIV-1 was EGFP-1 > Vif > EGFP-2 > HSA > G
ag (all p values  <  0.001). Despite being much less fre-
quent, HIV-2 G-to-A hypermutants were also concen-
trated mainly in the EGFP-1 and Vif amplicons, although 
differences between amplicons did not reach statistical 
significance. These observations indicate that G-to-A 
hypermutation can significantly vary between different 
genes and even between different regions of the same 
gene (i.e. EGFP-1 vs. EGFP-2).
G-to-A hypermutation was further analyzed by deter-
mining the number of G-to-A mutations per hypermu-
tant read pair. Most G-to-A hypermutants contained low 
numbers of G-to-A mutations (medians of 4 for both 
viruses), as expected for these short (~120 bp) read pairs 
(Figure 3c). However, a minority of G-to-A hypermutants 
contained high numbers of G-to-A mutations (maxima 
of 22 and 21 for HIV-1 and HIV-2, respectively). In con-
trast to the biological samples, the ultra-rare G-to-A 
hypermutants observed in the plasmid controls nearly all 
contained only two G-to-A mutations (one triple G-to-A 
mutant was observed for the HIV-2 plasmid). Next, the 
dinucleotide contexts of G-to-A mutations in hypermu-
tants were analyzed, as APOBEC3 proteins are strongly 
associated with GG or GA dinucleotide contexts [42–45], 
depending on the specific APOBEC3 family member. 
Most G-to-A mutations were found within the GA dinu-
cleotide context for both viruses, and, strikingly, only 1% 
(HIV-1) or 4% (HIV-2) were found to occur in either the 
GT or GC sequence contexts (Figure 3d). These dinucle-
otide contexts were markedly different from the contexts 
of the rare G-to-A hypermutants identified in the plasmid 
controls (Figure 3d) as well as from the contexts of single 
G-to-A mutants (Additional file 8: Figure S3). Although 
the dinucleotide context appears to differ between the 
HIV-1 and HIV-2 plasmid controls, it should be noted 
that these contexts are based on extremely low numbers 
of hypermutants for the plasmids (10 for HIV-1 and 17 
for HIV-2). The observed bias in the virological samples 
was not caused by a higher prevalence of the GA dinucle-
otide (relative to GG, GC, and GT) within the amplicon 
sequences, as GA dinucleotides only accounted for 24% 
of all guanine-containing dinucleotides. Taken together, 
these findings support the conclusion that the low level 
of G-to-A hypermutation observed was primarily caused 
by one or more APOBEC3 family members, despite the 
presence of Vif in our experimental system.
The patterns of G-to-A hypermutation were further 
characterized by investigating whether G-to-A mutations 
in hypermutants occurred at hotspots and, if so, whether 
sequence preferences (beyond the dinucleotide context) 
could be identified. In this analysis, we defined G-to-
A hypermutation hotspots as statistical upper outliers 
using the 1.5× interquartile range (IQR) rule. Using this 
criterion, 18 (HIV-1) or 16 (HIV-2) hotspots for G-to-A 
hypermutation were identified, all of which were located 
in the Vif or EGFP-1 amplicons (Additional file 9: Table 
S4). Of these, 14 (13 in EGFP-1 and 1 in Vif ) were shared 
between HIV-1 and HIV-2, suggesting a common mecha-
nism of mutation. Because specific APOBEC3 proteins 
have been shown to exhibit additional sequence prefer-
ences at the −1 and +2 positions (relative to the mutated 
guanine), sequence logos for total G-to-A hypermutation 
hotspots, GA context hotspots, and GG context hotspots 
were generated. However, statistically significant prefer-
ences at other positions were not observed for HIV-1 or 
HIV-2 in any of these categories. Furthermore, in order 
to gauge the potential effects of hypermutation on pro-
tein expression and/or function, the coding changes 
introduced at G-to-A hypermutation hotspots were 
examined (Additional file  9: Table S4). G-to-A hyper-
mutation did not result in the introduction of premature 
stop codons at any of the examined hotspots. Missense 
mutations were typically R-to-K (semi-conservative), 
D-to-N (semi-conservative), or E-to-K (non-conserva-
tive); however, other types were occasionally observed. 
Interestingly, several of the Vif mutations occurring in 
G-to-A hypermutants at these hotspots have been previ-
ously characterized (see “Discussion”) [15].
HIV‑1 and HIV‑2 mutation frequencies and spectra 
are not significantly different in the absence of G‑to‑A 
hypermutants
The HIV-1 and HIV-2 mutational data was analyzed with 
and without G-to-A hypermutants in order to: (1) esti-
mate the extent to which G-to-A hypermutation con-
tributed to the total mutational data, and (2) determine 
whether G-to-A hypermutation was primarily responsi-
ble for observed differences between HIV-1 and HIV-2 
mutation frequencies and spectra. While removal of 
G-to-A hypermutants had little effect on HIV-2 muta-
tion frequencies (reducing the total mutation frequency 
by only 5%), their removal reduced the overall HIV-1 
mutation frequency by 53% and the G-to-A transition 
mutation frequency by 81% (Figure  4a). Thus, G-to-
A hypermutation was responsible for approximately 
half of all mutations observed in HIV-1, despite being a 
relatively rare event (~1 of 127 read pairs were G-to-A 
Page 8 of 17Rawson et al. Retrovirology  (2015) 12:60 
hypermutants). In the absence of G-to-A hypermutants, 
HIV-1 and HIV-2 total mutation frequencies were found 
to be 3.2 or 2.9 × 10−4 m/bp, respectively, a 1.1-fold dif-
ference that was not statistically significant (p  =  0.14; 
Figure  4a). However, as noted earlier, HIV-2 displayed 
an ~1.1-fold lower frequency of A-to-G transitions 
(p = 0.049) and an ~1.5-fold higher frequency of C-to-T 
transitions (p =  0.0019) than HIV-1, and these findings 
were not altered by the removal of G-to-A hypermutants. 
Further, HIV-1 still demonstrated an ~1.8-fold higher 
frequency of G-to-A transitions (p  <  0.001) than HIV-2 
after removal of G-to-A hypermutants. As expected, the 
mutation spectra for HIV-1 and HIV-2 were also much 
more comparable in the absence of the G-to-A hypermu-
tation data (compare Figures 4b, 2c), although HIV-1 dis-
played a somewhat higher percentage of G-to-A (27 vs. 
17%) and lower percentage of C-to-T (14 vs. 23%) tran-
sitions than HIV-2. Taken together, these observations 
suggest that most of the observed differences in viral 
mutation patterns between HIV-1 and 2 were due to the 
highly reduced levels of G-to-A hypermutants for HIV-
2. These findings imply that the fidelities of other muta-
tional sources, such as RT, are relatively similar for HIV-1 
and HIV-2.
Discussion
Detection of rare mutations is often difficult with next-
generation sequencing technologies due to high error 
rates, which for Illumina platforms typically range from 
~10−2 m/bp for unfiltered data and ~10−3 to 10−4 m/bp 
for stringently filtered data [33–35, 46–49]. We adopted 
numerous measures to minimize background errors due 
Figure 4 HIV-1 and HIV-2 mutation frequencies and spectra are similar in the absence of G-to-A hypermutation. a Analysis of mutation frequency 
in the absence of G-to-A hypermutation. HIV-1 and HIV-2 mutation frequencies were determined either including or excluding G-to-A hypermu-
tants, with the results superimposed. The relative percentage of the total data that can be attributed (or not attributed) to G-to-A hypermutation is 
indicated within the bars. b Analysis of HIV-1 and HIV-2 mutation spectra in the absence of G-to-A hypermutation. HIV-1 and HIV-2 mutation spectra 
were examined after excluding all G-to-A hypermutants. Mutation spectra were determined by dividing the frequency of each type of mutation by 
the total mutation frequency, with the results expressed as a percentage. Data in both panels represent the mean of three experimental replicates.
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to PCR and sequencing, as well as to minimize PCR-
mediated recombination (see “Methods”). We also per-
formed control amplifications from plasmids in which we 
matched conditions as closely as possible with the biolog-
ical samples. After stringent filtering, we obtained error 
frequencies of 2.8 (HIV-1) or 2.6 (HIV-2) ×  10−4 m/bp 
for the plasmid controls (Figure 2a). The frequencies and 
distribution of background errors were nearly identical 
between the HIV-1 and 2 plasmid controls (Figure 2a–c), 
as expected considering that the amplicons were either 
identical (HSA, EGFP-1, EGFP-2) or ~60% homologous 
(Gag, Vif ) in sequence. Consistent with previous reports 
on Illumina background errors [33–36, 49], the spectra 
of background errors were more heavily biased toward 
transversions than biological samples (Figure 2c), specifi-
cally C-to-A and G-to-T transversions (Additional file 4: 
Figure S1). This trend was observed despite prior mask-
ing of plasmid error hotspots, which were also mostly 
(~83%) C-to-A and G-to-T transversions (see “Methods” 
and Additional file  10: Table S5). Two mechanisms for 
these transversion types have been suggested in the lit-
erature [33–36, 50]: (1) oxidative conversion of guanine 
to 8-oxoguanine during sample processing, which would 
lead to fixation of C-to-A and G-to-T mutations during 
PCR, and (2) imaging errors that result from crosstalk 
between the C and A channels or between the G and T 
channels, as the fluorophores attached to these bases are 
excited by the same lasers and then distinguished using 
different filters. Due to these issues, we unfortunately 
were not able to make a detailed comparison of transver-
sion frequencies between HIV-1 and 2. However, transi-
tion frequencies [5.8 (HIV-1) and 2.0 (HIV-2) × 10−4 m/
bp] were significantly higher than the plasmid controls 
for both viruses (HIV-1: p  <  0.001; HIV-2: p  =  0.038), 
and many previous reports have established transitions 
as the dominant type of mutations that occur during 
HIV-1 replication [1–4, 17, 19, 40]. Thus, further analyses 
focused primarily on these mutational types.
Relative to previous estimates of the HIV-1 mutation 
rate (which range from 1.4 to 8.5 × 10−5 mutations/bp/
cycle) [1–5, 17, 41, 51], we obtained a somewhat higher 
mutation frequency for HIV-1 of 6.9  ×  10−4  m/bp (or 
5.8 ×  10−4 m/bp if considering only transitions). How-
ever, these discrepancies may be due to several key dif-
ferences between the assays used and the ways in which 
the data were analyzed. First, the level of background 
error in previous studies was likely much lower. Most 
previous estimates of the HIV-1 mutation rate were 
determined using the LacZα assay [1, 2, 4, 17, 41], in 
which a proviral lacZα sequence is purified (using the 
Lac repressor or Hirt extraction), directly transformed 
into E. coli (without using PCR), and subjected to blue/
white color screening, followed by Sanger sequencing of 
mutants. While this assay results in little background, 
it is low-throughput and can only detect and meas-
ure mutations within the lacZα marker gene. Second, 
previously used marker gene assays (such as the LacZα 
assay) necessarily underestimate true mutation rates 
because they only detect mutations leading to a pheno-
typic change (silent mutations are not detected unless 
co-occurring with other mutations). For the LacZα assay, 
measured mutation rates are thought to underestimate 
actual mutation rates by ~2 to 3-fold [4]. In contrast, 
the assay we used based on direct PCR and Illumina 
sequencing of multiple amplicons should detect all 
mutations, provided that they do not prevent amplifica-
tion. Third, most previous studies used a second marker 
gene (typically an antibiotic resistance gene) to select for 
infected cells or to select for transformed E. coli [1–4, 17, 
41, 51]. This approach will not detect heavily mutated 
sequences (such as hypermutants) in which both marker 
genes are mutated and functionally disrupted. Fourth, 
actual mutation frequencies may vary between the genes 
analyzed here (gag, vif, hsa, and egfp) and mutational tar-
gets from previous studies. Fifth, many previous studies 
scored mutants harboring multiple mutations as single 
mutants for the purposes of calculating mutation rates 
[1, 2, 4, 17, 41, 51]. Also, in some cases background error 
frequencies were subtracted from the mutation frequen-
cies of the biological samples in order to calculate muta-
tion rates [5].
Unexpectedly, we identified G-to-A hypermutants for 
both HIV-1 and 2, though the frequency was much higher 
(~28-fold) for HIV-1 than HIV-2 (Figure  3a; p  <  0.001). 
The presence of G-to-A hypermutants could not be 
attributed to background errors, as their frequencies were 
much higher in the biological samples than in the plasmid 
controls. Also, the patterns of G-to-A hypermutation (in 
terms of dinucleotide context preferences and hypermu-
tation hotspots) were markedly distinct between the bio-
logical samples and plasmid controls (Figure 3d and data 
not shown). Unlike single G-to-A mutants from the bio-
logical samples, G-to-A hypermutants exhibited a strong 
bias toward GA dinucleotide contexts (Figure  3d; Addi-
tional file 8: Figure S3). In sum, these findings support the 
idea that the G-to-A hypermutants were caused by low-
level activity of one or more APOBEC3 proteins. How-
ever, APOBEC3G cannot be primarily responsible, due 
to its strong preference for GG dinucleotides [42–44, 52]. 
Further experiments in which specific APOBEC3 proteins 
are down-regulated (through knockout or knockdown) 
are required to prove that the G-to-A hypermutants we 
observed are APOBEC3-mediated, as well as to identify 
the specific APOBEC3 protein(s) responsible.
The observation of G-to-A hypermutation was some-
what surprising because: (1) the HIV-1 and HIV-2 
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vectors used in these studies encoded for a functional 
Vif protein, (2) the expression levels of most APOBEC3 
proteins are relatively low in 293T (i.e., the cells that pro-
duced the HIV-1 and HIV-2 vector viruses) [19], and 
(3) Vif-proficient and Vif-deficient viruses exhibit simi-
lar infectivities when produced in 293T cells [13, 15, 32, 
53]. Upon observing G-to-A hypermutation, we con-
firmed via Sanger sequencing that the vif genes in the 
HIV-1 and HIV-2 vectors were intact (data not shown). 
Notably, previous studies have demonstrated that Vif 
does not always fully neutralize the activity of APOBEC3 
proteins [13, 42, 54–56]. In addition, Vif from different 
subtypes or containing naturally occurring polymor-
phisms have been shown to vary widely in their neutrali-
zation capacities [55–57]. Further, multiple APOBEC3 
proteins (including B, C, D, and F) have been detected 
at the mRNA level in 293T cells and could be involved 
in the observed G-to-A hypermutation [19, 58]. Previ-
ous studies by our group have identified rare G-to-A 
hypermutants occurring at GA dinucleotides by Sanger 
sequencing of clones (in which case the virus stocks were 
also generated in 293T cells) [19, 59]. Taken together, the 
G-to-A hypermutation observed here was likely due to 
the failure of HIV-1 or HIV-2 Vif to fully neutralize low 
levels of APOBEC3 proteins present in 293T producer 
cells. Consistent with this hypothesis, G-to-A hypermu-
tation was observed very infrequently even for HIV-1 (~1 
of 127 read pairs were G-to-A hypermutants), despite 
contributing to about half of all mutations (Figure  4a). 
Although HIV-2 was less susceptible than HIV-1 to G-to-
A hypermutation in this experimental system, further 
investigation will be required to determine whether these 
trends hold true under conditions of higher APOBEC3 
expression. Intriguingly, HIV-2 ∆vif has been reported 
to be less sensitive than HIV-1 ∆vif to APOBEC3G [32], 
but susceptibilities to other APOBEC3 proteins (in the 
presence or absence of Vif ) have not yet been compared. 
Further, HIV-1 and HIV-2 Vif were recently shown to 
interact with APOBEC3F and APOBEC3G through com-
pletely separate sequence determinants, and differences 
in HIV-1 and HIV-2 Vif-induced degradation of specific 
APOBEC3 proteins were also noted [60].
Most of the G-to-A hypermutants occurred within 
the EGFP-1 and Vif amplicons (Figure 3b). This may be 
due in part to higher frequencies of GA dinucleotides 
in these particular amplicons. For HIV-1, the frequen-
cies of GA dinucleotides (relative to GG, GT, and GC) 
were 13% (Gag), 32% (Vif ), 9% (HSA), 32% (EGFP-1), 
and 30% (EGFP-2). Thus, the GA dinucleotide frequency 
varied maximally by 3.6-fold, whereas G-to-A hyper-
mutation frequencies varied up to 26.3-fold (EGFP-1 
vs Gag). However, APOBEC3-mediated hypermutation 
can also be influenced by broader sequence contexts 
and secondary structures [14, 15, 42, 44, 61–63]. Fur-
ther, APOBEC3 activity follows a twin gradient along 
the HIV-1 genome corresponding to the amount of time 
the minus strand viral DNA remains single-stranded, 
such that the positioning of the amplicon could affect 
hypermutant frequencies [64, 65]. Thus, one or more of 
these other features may have favored hypermutation in 
the EGFP-1 and Vif amplicons. Full genome sequencing 
will be required to address the distribution of G-to-A 
hypermutation in more detail. G-to-A hypermutation 
hotspots were also identified (Additional file  9: Table 
S4), which all occurred in the EGFP-1 and Vif amplicons. 
G-to-A hotspots did not result in any nonsense muta-
tions, consistent with the notion that GA dinucleotide-
biased hypermutation generates fewer stop codons than 
GG-biased hypermutation. However, the G-to-A hot-
spots did introduce a number of missense mutations, 
particularly D-to-N, E-to-K, and R-to-K. Surprisingly, 
all of the mutations resulting from the four hotspots in 
HIV-1 Vif were recently identified in another study in 
which humanized mice were infected with an HIV-1 var-
iant that cannot neutralize APOBEC3D or F [15]. One of 
these Vif mutants (E134K) lost the ability to neutralize 
APOBEC3G, raising the possibility that hypermutation 
itself can influence susceptibility to hypermutation in 
further rounds of replication.
We initially hypothesized that HIV-2 would exhibit a 
lower mutation frequency than HIV-1 due to its attenu-
ated pathogenicity, reduced evolutionary rate [27, 28], a 
conserved fidelity-improving V75I polymorphism in RT 
[30, 31], and reduced susceptibility to APOBEC3G [32]. 
More specifically, HIV-2 Env has been found to diversify 
more slowly than HIV-1 Env when compared to HIV-
1-infected individuals with high viral loads [28]. How-
ever, HIV-1 and HIV-2 diversification rates were similar 
when compared to HIV-1-infected individuals with low 
viral loads. In the same report, HIV-2 Env was found to 
evolve more slowly than HIV-1 Env and to be subject 
to strong purifying selection. Indeed, HIV-2 infection 
appears to elicit broad and potent neutralizing antibody 
responses against Env more frequently than for HIV-1 
[66]. In another report, HIV-2 Env was found to exhibit 
a lower rate of synonymous substitutions than HIV-
1, implying reduced viral mutation and/or replication 
rates [27], though another group has reported oppos-
ing findings [29]. Unfortunately, it is difficult to compare 
the results of our analyses to these published reports 
due to these contradicting results, and larger studies of 
HIV-2 intra-patient diversification and evolution are 
clearly warranted. Nonetheless, we found that HIV-1 and 
HIV-2 exhibited similar total mutation frequencies in the 
absence of G-to-A hypermutants, suggesting that differ-
ences in replication fidelity do not have a major impact 
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on differences in evolutionary or synonymous substitu-
tion rates between HIV-1 and HIV-2.
Conclusions
In sum, we have found that HIV-2 exhibited significantly 
lower total and transition mutation frequencies than HIV-
1, as well as a mutation spectrum less biased toward G-to-
A transitions. However, these differences were mostly due 
to a significantly higher G-to-A hypermutation frequency 
for HIV-1 than HIV-2. These findings raise the intriguing 
possibility that HIV-2 might be less sensitive than HIV-1 
to APOBEC3-mediated hypermutation, consistent with a 
previous report [32], but additional experiments in other 
cell types will be required to fully address this question. 
After removal of all G-to-A hypermutants, HIV-1 and 
HIV-2 total mutation frequencies were not significantly 
different, although small but significant differences were 
still observed in the frequencies of G-to-A and C-to-T 
transitions. Overall, these results suggest that the fidelities 
of other mutagenic processes (such as reverse transcrip-
tion) are relatively similar between the two viruses. Nev-
ertheless, we cannot rule out the possibility that HIV-1 
and HIV-2 exhibit more minor differences in mutation 
frequencies or spectra that we were not able to detect or 
that differences would be observed in other cell types. 
Overall, these data imply that differences in replication 
fidelity are likely not a major contributing factor to the 
unique clinical features of HIV-2 infection.
Methods
Plasmids, cell lines, and reagents
The HIV-1 vector, pNL4-3 HIG, has been previously 
described [67]. This vector contains a cassette encoding 
heat stable antigen (HSA), an internal ribosomal entry site 
(IRES), and enhanced green fluorescent protein (EGFP). 
The HIV-2 vector, pROD HIG, was created from pHIV-2 
H0G [68], a kind gift from Dr. Wei-Shau Hu (HIV Drug 
Resistance Program, Frederick National Laboratory for 
Cancer Research, Frederick, MD, USA). The pHIV-2 
H0G vector does not express Vpr or EGFP due to mul-
tiple point mutations. In order to construct pROD HIG, 
the vpr and egfp genes were restored by site-directed 
mutagenesis using the QuikChange II XL kit (Agilent 
Technologies, Inc.; Santa Clara, CA, USA), and the result-
ing vector was verified by DNA sequencing. Both HIV-1 
and HIV-2 vectors contain intact open reading frames 
for all genes except for the env and nef genes. Vector viral 
stocks from pNL4-3 HIG were produced by co-transfect-
ing with pNL4-3 Env, a kind gift from Dr. Eric Freed (HIV 
Drug Resistance Program, Frederick National Laboratory 
for Cancer Research, Frederick, MD, USA). Vector viral 
stocks of pROD HIG were produced by co-transfecting 
pROD10-Env [69], a kind gift from Dr. Paula Cannon 
(University of Southern California, Los Angeles, CA, 
USA). The human embryonic kidney (HEK 293T) cells 
were purchased from American Type Culture Collection 
(Manassas, VA, USA) and maintained in Dulbecco’s Mod-
ified Eagle’s Medium (DMEM) from Cellgro (Manassas, 
VA, USA) with 10% HyClone FetalClone III (FC3) from 
Thermo Scientific (Waltham, MA, USA) and 1% penicil-
lin/streptomycin from Life Technologies (Grand Island, 
NY, USA). U373-MAGI-CXCR4CEM cells were obtained 
from Dr. Michael Emerman through the NIH AIDS 
Reagent Program, Division of AIDS, NIAID, NIH [70]. 
U373-MAGI cells were maintained similarly to 293T cells 
but with addition of 1.0  μg/mL puromycin, 0.1  mg/mL 
hygromycin B, and 0.2 mg/mL G418 to the medium. For 
transfections, poly-l-lysine was from Newcomer Supply 
(Middleton, WI, USA) and polyethylenimine (PEI) was 
from Polysciences, Inc. (Warrington, PA, USA).
Virus production and titering
Virus was produced by co-transfecting pNL4-3 HIG or 
pROD HIG with pNL4-3 Env or pROD10 Env, respec-
tively, into 293T cells via the PEI method [71]. PEI stocks 
were prepared at 1  mg/mL by dissolving PEI in water, 
adjusting the pH to 7.0, and filtering through a 0.2  µm 
filter. 24 h before transfection, 4 million 293T cells/plate 
were seeded onto 10 cm plates pre-coated for 5 min with 
poly-l-lysine. For each plate, 10  µg of pNL4-3 HIG or 
pROD HIG + 5 µg Env expression plasmid + 45 µL 1 mg/
mL PEI were combined with serum-free DMEM to a final 
volume of 1 mL. After 20 min of incubation, the medium 
on the 293T cells was replaced and the DNA-PEI mixture 
was added. The medium was replaced 16 h post-transfec-
tion, and viral stocks were collected 48  h post-transfec-
tion by filtering the supernatants through a 0.2 µm filter. 
For each viral stock, five plates were transfected, and the 
resulting supernatants were pooled and concentrated 
(~tenfold) using 100,000 MWCO filtration columns 
(Vivaproducts; Littleton, MA, USA). Viral stocks were 
then treated with 10 U/mL of DNase I (New England Bio-
labs; Ipswich, MA, USA) for 2 h at 37°C to degrade resid-
ual plasmid DNA from transfections. Viral stocks were 
then divided into 1.0 mL aliquots and frozen at −80°C.
Prior to large-scale infections, viral stocks were first 
titered in U373-MAGI cells based on EGFP expression. 
The day before infection, 31,250 cells/well were plated 
in 24-well plates. After 24 h, the media was replaced and 
varying volumes of virus ranging from 15.625 to 500 µL 
(twofold dilution series) were added. To improve infec-
tivity, the cells were infected by spinoculation (1,200 × g 
for 2  h at 24°C). The media was replaced again 24  h 
post-infection and cells were collected at 72  h post-
infection for analysis of EGFP expression by flow cytom-
etry. The cells were treated with trypsin, transferred 
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to 96-well plates, pelleted at 500  ×  g for 5  min, and 
resuspended in 200  µL Dulbecco’s phosphate-buffered 
saline (DPBS) +  2% FC3/well. EGFP expression from at 
least 10,000 gated cells was analyzed using a BD LSR II 
flow cytometer (BD Biosciences; San Jose, CA, USA). 
EGFP was excited with a blue 488-nm laser and emis-
sion detected using 505LP and 525/50 filters. Virus titers 
(expressed as infectious units/mL) were calculated based 
upon EGFP expression at low infectivities (<40%) as pre-
viously described [72].
Infections for Illumina sequencing
In order to prepare samples for Illumina sequencing, 
1 ×  106 U373-MAGI cells were infected at a multiplic-
ity of infection (MOI) of 1.0. These infections were per-
formed in 24-well plates (31,250 cells/well) in order to 
avoid any potential effect of the plate format on infec-
tious titer. Uninfected cells and cells infected with heat-
inactivated viruses (i.e. virus stocks that were incubated 
at 65°C for 1 h) were included as negative controls. The 
cells were infected by spinoculation, and the medium 
was replaced 24 h post-infection. Cells were collected for 
genomic DNA extraction at 72 h post-infection by treat-
ing with trypsin, pelleting, and washing three times with 
DPBS to further reduce plasmid carryover. Extra wells of 
infected cells were analyzed by flow cytometry to verify 
infectivity. In this assay, all proviruses result from a sin-
gle cycle of infection, as neither producer cells nor target 
cells can be re-infected, due to a lack of the appropriate 
receptor and co-receptor or to a lack of envelope expres-
sion, respectively (Figure 1).
Genomic DNA extraction and quantification of plasmid 
carryover
Genomic DNA was extracted from all collected cells 
using the High Pure PCR Template Preparation Kit 
(Roche; Basel, Switzerland) following the manufacturer’s 
instructions and eluted in 150 μL buffer. Genomic DNA 
was treated with DpnI for 1  h at 37°C to further reduce 
plasmid carryover from the transfections, after which 
DpnI was heat-inactivated at 80°C for 20 min. In order to 
quantify any residual plasmid carryover, two approaches 
based on quantitative PCR (qPCR) were adopted: (1) 
the ampicillin resistance gene copy number was deter-
mined and divided by the proviral copy number (as 
measured using the HSA Illumina amplicon), or (2) the 
proviral copy number from heat-inactivated virus infec-
tions was determined and divided by the proviral copy 
number from the corresponding un-treated infections. 
For both approaches, qPCR was performed using 4  μL 
water, 6.25 μL 2× Power SYBR Green Master Mix (Life 
Technologies), 0.625 μL each primer (500 nM final con-
centration), and 1  μL template. The cycling conditions 
used were an initial denaturation of 95°C 10 m, 40 cycles 
of 95°C 15 s/55°C 15 s/72°C 30 s, and a final extension of 
72°C 7 min. The sequences of the primers to the ampicil-
lin resistance gene were 5′-ACTTTATCCGCCTCCATC 
CAGTC-3′ and 5′-GAGCGTGACACCACGATGC-3′. 
Absolute standard curve series (from 101 to 106 copies/
μL) were constructed by quantifying the pNL4-3 HIG and 
pROD HIG plasmids with the Qubit dsDNA HS Assay Kit 
(Life Technologies). We found that the level of plasmid 
carryover for HIV-1 was 0.2% when measured by either 
method, while the level of carryover was 2.8 or 1.4% for 
HIV-2, depending on the approach used (Additional file 1: 
Table S1). These results are comparable to those obtained 
in a similar study of HIV-1 mutagenesis [5] and are too 
low to significantly affect measured mutation frequencies.
Amplifications for Illumina sequencing
PCR was performed on five small (~150–170 bp) ampli-
cons (Gag, Vif, HSA, EGFP-1, EGFP-2) for each sample, 
with HIV-1 and 2 amplicons positioned in homologous 
locations. All forward primers contained 5-base barcodes 
(differing by at least two bases) to allow demultiplexing of 
pooled PCR products. All primer and barcode sequences 
are listed in Additional file  11: Table S6. Barcodes were 
randomly generated using a program written by Luca 
Comai and Tyson Howell (http://comailab.genomecenter.
ucdavis.edu/index.php/Barcode_generator) [73]. PCR 
was performed using the Phusion Hot Start II High-
Fidelity DNA Polymerase (Fisher Scientific; Pittsburgh, 
PA, USA). PCR reactions were performed with 8  µL of 
genomic DNA (~50,000 target copies), 500  nM of each 
primer, and a final volume of 50 µL/reaction. The cycling 
conditions used were an initial denaturation of 98°C 30 s, 
30 cycles of 98°C 10  s/56°C 30  s/72°C 15  s, and a final 
extension of 72°C 10  min. All PCR reactions were per-
formed in triplicate to reduce the risk of clonal amplifi-
cation, and the products were pooled after amplification. 
Negative control reactions were performed lacking tem-
plate or with genomic DNA from uninfected cells.
In order to assess the degree of background error due 
to PCR and Illumina sequencing, control amplifications 
were performed from pNL4-3 HIG or pROD HIG plas-
mids using the same cycling conditions. For these reac-
tions, 50,000 copies of plasmid per 50  µL reaction was 
used, a target level found via qPCR to be similar to that of 
the other samples. Genomic DNA (8  µL/reaction) from 
uninfected cells was added to the plasmid PCR reactions 
to account for any potential impact of genomic DNA on 
amplification. Further, the degree of intra-sample PCR-
mediated recombination was investigated in the plasmid 
controls, as recombination could affect the association 
between mutations and thus alter hypermutant frequen-
cies. To determine recombination frequencies, EGFP-1 
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was amplified from a 1:1 mixture (i.e. 25,000 copies 
each) of wild-type and mutant EGFP-1 sequences. The 
mutant EGFP-1 sequence contained two genetic mark-
ers positioned ~50 bp apart, and each marker consisted 
of two mutations to facilitate distinction from PCR and 
sequencing-induced errors. Intra-sample recombinants 
were detected by identifying read pairs from the plas-
mid controls with a single marker set, rather than the 
expected zero or two marker sets present in the wild-type 
and mutant EGFP-1 sequences, respectively. Importantly, 
all mutations utilized as recombination markers were 
masked before mutational analysis.
Library preparation and Illumina sequencing
Amplicons were gel-purified using the Promega SV Gel 
Extraction Kit (Promega Corp.; Madison, WI, USA). 
After gel purification, all amplicons were quantified 
using the Qubit dsDNA HS Assay Kit (Life Technolo-
gies) and a Qubit 2.0 fluorometer. For each sample, all 
amplicons were pooled together in an equimolar fash-
ion to normalize coverage between amplicons. Next, 
100 ng of each sample (12 samples in total) were submit-
ted to the University of Minnesota Genomics Center for 
library preparation. The libraries were constructed with 
the TruSeq Nano DNA Sample Preparation Kit follow-
ing the manufacturer’s instructions but using AMPure 
XP beads (Beckman Coulter, Inc.; Indianapolis, IN, USA) 
at a bead to sample ratio of 1.8. The 15 libraries were 
again quantified using the Qubit dsDNA BR Assay Kit, 
size-confirmed with Agilent DNA 1000 chips (Agilent 
Technologies; Santa Clara, CA, USA), and pooled in an 
equimolar fashion to normalize coverage between librar-
ies. Samples were pooled after library preparation, rather 
than before, because it had been previously determined 
that significant inter-sample recombination can occur 
during the 10 cycles of PCR typically utilized in library 
construction (data not shown). In order to improve 
sequence diversity and quality, a PhiX library was added 
in at ~25% of total mass. Next, 2 μL of the 10 nM library 
pool was denatured and diluted to a final concentration 
of 4  pM for DNA sequencing. Sequencing of proviral 
DNA was conducted by using the Illumina MiSeq with 
2 × 150 paired-end sequencing. All Illumina sequencing 
data supporting the results of this manuscript have been 
deposited into the NCBI Sequence Read Archive (SRA) 
under accession code BioProject PRJNA287455.
Processing of proviral DNA sequencing data
First, paired-end reads from the Illumina MiSeq reaction 
were demultiplexed based on perfect barcode matches, 
and barcode sequences were trimmed off during the pro-
cess. Second, poor quality reads were filtered out using 
quality criteria found to reduce Illumina background 
error rates [35]. Specifically, read pairs were discarded in 
which either read contained a B-tail (i.e. one or more low 
quality bases at the end of the read), contained at least 
one uncalled base, had less than two-thirds of bases with 
Q-score ≥30 in the first half of the read, or had an aver-
age Q-score <30 in the first 30% of the read. Third, reads 
from each of the 12 samples were mapped to the appro-
priate reference sequence (pNL4-3 HIG or pROD HIG) 
with GSNAP [74] using default parameters. Finally, a 
small number of read pairs (~35,000) that were aligned 
either partially or fully outside of the appropriate ampli-
con regions were excluded. For each sample, the numbers 
of initial read pairs, read pairs lost during mapping or fil-
tering, and final read pairs are listed in Additional file 2: 
Table S2. We obtained ~4.7 million total read pairs after 
all processing steps, which removed primarily PhiX read 
pairs or HIV read pairs with imperfect barcodes or poor 
quality. About 319,000–461,000 read pairs were obtained 
per sample (average of 395,000 read pairs/sample), or 
46,000–111,000 read pairs per amplicon per sample 
(average of 79,000 read pairs/amplicon/sample).
In order to identify mutations present in read pairs 
passing the above processing steps, a custom algorithm 
was developed to compile mutation frequency data for 
each sample, built using the Genome Analysis Toolkit 
(GATK) walker framework [75]. This algorithm deter-
mines both the frequency of total mutations as well as 
of specific mutational types (substitutions, transitions, 
transversions, every type of transition or transversion, 
insertions, deletions, etc.). In order to minimize back-
ground error rates, mutations were required to be identi-
fied on both sequences in a read pair, which was possible 
because forward and reverse reads were mostly overlap-
ping due to small amplicon sizes (~150–170 bp). Further-
more, substitutions and insertions were only counted if 
they had a Q-score ≥30 for the relevant base(s) on both 
reads. Wild-type bases had to meet the same criteria as 
mutations (i.e. identified as wild-type and Q-score ≥30 
on both sequences of a read pair). Non-overlapping seg-
ments of read pairs as well as single reads were excluded 
from mutational analyses. All primer sequences were 
also excluded from mutational analysis, as errors within 
primers would not represent biologically meaningful 
mutations. We also examined the distribution of all back-
ground errors (from PCR and sequencing) in the plasmid 
controls and identified numerous plasmid error hotspots 
(defined as upper outliers within the distribution of fre-
quencies of individual mutations based on the 1.5 × IQR 
rule). Most plasmid error hotspots (~83%) were G-to-
T or C-to-A transversions. Within identical amplicons 
(HSA/EGFP-1/EGFP-2), many common plasmid error 
hotspots were identified in the HIV-1 and HIV-2 plasmid 
controls (~88% overlap), whereas the degree of overlap 
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was much lower for the ~60% homologous viral ampli-
cons (~49% overlap in Gag and ~31% overlap in Vif ). 
Plasmid error hotspots that were shared between the 
HIV-1 and HIV-2 plasmid controls (Additional file  10: 
Table S5) were masked before further downstream analy-
sis, as the presence of these mutations in the biological 
samples would most likely represent background errors. 
Rather than masking all mutational types at error hot-
spots, only the problematic type(s) (e.g. G-to-T) were 
masked at the indicated positions. Insertions and dele-
tions were scored as single events regardless of the num-
ber of bases inserted or deleted. Mutation frequencies 
(defined as mutations/bp) were calculated by dividing the 
number of mutations passing filters by all reference bases 
(mutations + wild-type bases) passing filters.
In addition to examining mutation frequencies and 
spectra, hypermutants were identified and character-
ized within the Illumina sequencing data. Using a custom 
GATK walker, hypermutant counts for each type of tran-
sition were collected (G-to-A, A-to-G, T-to-C, and C-to-
T). Hypermutants were defined as individual read pairs 
containing two or more of the same type of transition. 
All transitions had to be identified on both sequences 
with Q-scores ≥30, and a single read pair could theo-
retically count as two different types of hypermutants if 
it contained multiple instances of two different transi-
tion types. Hypermutant frequencies were calculated 
by dividing the number of hypermutant read pairs by 
all (hypermutant  +  non-hypermutant) read pairs that 
passed the processing steps. In order to examine G-to-A 
hypermutation hotspots, ranked lists of G-to-A mutation 
frequencies were generated at individual bases within 
G-to-A hypermutants. Hypermutation hotspots were 
then defined as statistical upper outliers within the distri-
bution of frequencies using the 1.5 × IQR rule.
Biostatistical analysis of Illumina DNA sequencing data
To test for factors that may influence mutation frequen-
cies, generalized linear mixed effects models were applied 
to the data that came from our Illumina data processing 
pipeline. The raw counts for each type of mutation (e.g. 
transitions) were modeled as Poisson random variables 
with an offset given by the total number of reference bases. 
The type of sample (i.e. HIV-1, HIV-2, and plasmid con-
trols for HIV-1 and HIV-2), the type of amplicon, and their 
interactions were treated as fixed effects while the replicate 
was treated as a random effect. The logarithmic link was 
used, as is standard for Poisson outcomes, and penalized 
quasilikelihood was used to estimate the model param-
eters [76]. These computations were conducted using R v 
3.1.0 and the MASS package. All figures and tables were 
created in GraphPad Prism v 6.0 (GraphPad Software, Inc.; 
La Jolla, CA, USA) or Microsoft Office for Mac 2011 v 
14.3.8 (Microsoft Corp.; Redmond, WA, USA).
Additional files
Additional file 1: Table S1. Quantification of plasmid carryover from 
virus production. The levels of HIV-1 or HIV-2 plasmids from transfections 
remaining in genomic DNA samples were determined using quantitative 
PCR-based approaches.
Additional file 2: Table S2. Output of 2 × 150 Illumina sequencing of 
HIV-1 and HIV-2 after data processing. For each sample, the numbers of 
read pairs before and after quality filtering are indicated, both grouped 
across all amplicons and separated by amplicon.
Additional file 3: Dataset S1. HIV-1 and HIV-2 mutation frequencies 
determined by Illumina sequencing. For each sample, this dataset lists the 
numbers of reference bases, mutations, mutation frequencies, and relative 
percentages of many different mutational types. The data is shown both 
grouped across all amplicons and separated by amplicon (as different tabs 
within the spreadsheet).
Additional file 4: Figure S1. Bias of transversion spectra toward C-to-A 
and G-to-T mutations. The transversion spectra for HIV-1 and HIV-2 bio-
logical samples and plasmid controls are illustrated, revealing a clear bias 
toward C-to-A and G-to-T transversion types, particularly for the plasmid 
controls.
Additional file 5: Table S3. Determination of intra-sample recombina-
tion frequencies from PCR. The frequency of intra-sample recombination 
resulting from PCR was determined using a set of genetic markers that 
were incorporated into the HIV-1 and HIV-2 plasmid controls.
Additional file 6: Dataset S2. HIV-1 and HIV-2 hypermutant frequen-
cies determined by Illumina sequencing. For each sample, this dataset lists 
the numbers of total read pairs, hypermutant read pairs, and hypermuta-
tion frequencies for all four possible types of transition hypermutants 
(G-to-A, A-to-G, C-to-T, T-to-C). Hypermutants were defined as read pairs 
(~ 120 bp in length) containing two or more of the same type of muta-
tion. The data is shown both grouped across all amplicons and separated 
by amplicon (as different tabs within the spreadsheet).
Additional file 7: Figure S2. Transition frequencies are similar across 
amplicons in the absence of G-to-A hypermutants. The frequencies of 
transitions were determined in all five amplicons after exclusion of all 
G-to-A hypermutants (individual read pairs containing two or more G-to-A 
mutations).
Additional file 8: Figure S3. Dinucleotide contexts of G-to-A mutations 
not occurring within G-to-A hypermutants. The dinucleotide contexts of 
all G-to-A mutations from HIV-1 and HIV-2 single mutants (i.e. non-hyper-
mutants) were determined, demonstrating the lack of a bias toward GA 
and/or GG dinucleotides.
Additional file 9: Table S4. Identification of G-to-A hypermutation 
hotspots in HIV-1 and HIV-2. G-to-A hypermutation hotspots were identi-
fied as statistical upper outliers according to the 1.5 × IQR rule. For each 
hotspot, the relative ranking, position, dinucleotide context, mutation 
frequency, and coding effects are indicated.
Additional file 10: Table S5. Identification and masking of plasmid 
error hotspots. Plasmid error hotspots (i.e. common sites for background 
errors due to PCR or sequencing) were identified by examining the distri-
bution of mutation frequencies at every individual position for the HIV-1 
and HIV-2 plasmid controls. Plasmid error hotspots were defined as upper 
outliers within the distribution using the 1.5 × IQR rule. Hotspots identi-
fied in both HIV-1 and HIV-2 plasmids were masked from all samples prior 
to mutational analyses, as they would most likely represent background 
errors in the biological samples.
Additional file 11: Table S6. HIV-1 and HIV-2 primer and barcode 
sequences for Illumina sequencing.
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